Publication

First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging

Dingemans, A. -M. C., de Langen, A. J., van den Boogaart, V., Marcus, J. T., Backes, W. H., Scholtens, H. T. G. M., van Tinteren, H., Hoekstra, O. S., Pruim, J., Brans, B., Thunnissen, F. B., Smit, E. F. & Groen, H. J. M., Mar-2011, In : Annals of Oncology. 22, 3, p. 559-566 8 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Dingemans, A. -M. C., de Langen, A. J., van den Boogaart, V., Marcus, J. T., Backes, W. H., Scholtens, H. T. G. M., ... Groen, H. J. M. (2011). First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging. Annals of Oncology, 22(3), 559-566. https://doi.org/10.1093/annonc/mdq391

Author

Dingemans, A. -M. C. ; de Langen, A. J. ; van den Boogaart, V. ; Marcus, J. T. ; Backes, W. H. ; Scholtens, H. T. G. M. ; van Tinteren, H. ; Hoekstra, O. S. ; Pruim, J. ; Brans, B. ; Thunnissen, F. B. ; Smit, E. F. ; Groen, H. J. M. / First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer : a phase II study including molecular imaging. In: Annals of Oncology. 2011 ; Vol. 22, No. 3. pp. 559-566.

Harvard

Dingemans, A-MC, de Langen, AJ, van den Boogaart, V, Marcus, JT, Backes, WH, Scholtens, HTGM, van Tinteren, H, Hoekstra, OS, Pruim, J, Brans, B, Thunnissen, FB, Smit, EF & Groen, HJM 2011, 'First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging', Annals of Oncology, vol. 22, no. 3, pp. 559-566. https://doi.org/10.1093/annonc/mdq391

Standard

First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer : a phase II study including molecular imaging. / Dingemans, A. -M. C.; de Langen, A. J.; van den Boogaart, V.; Marcus, J. T.; Backes, W. H.; Scholtens, H. T. G. M.; van Tinteren, H.; Hoekstra, O. S.; Pruim, J.; Brans, B.; Thunnissen, F. B.; Smit, E. F.; Groen, H. J. M.

In: Annals of Oncology, Vol. 22, No. 3, 03.2011, p. 559-566.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Dingemans A-MC, de Langen AJ, van den Boogaart V, Marcus JT, Backes WH, Scholtens HTGM et al. First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging. Annals of Oncology. 2011 Mar;22(3):559-566. https://doi.org/10.1093/annonc/mdq391


BibTeX

@article{cda1a26d251b42bb8e37464003b89e39,
title = "First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging",
abstract = "Background: Both bevacizumab and erlotinib have clinical activity in non-small-cell lung cancer (NSCLC). Preclinical data suggest synergistic activity.Patients and methods: Chemonaive patients with stage IIIb or IV non-squamous NSCLC were treated with bevacizumab 15 mg/kg every 3 weeks and erlotinib 150 mg daily until progression. Primary end point was non-progression rate (NPR) at 6 weeks. Tumor response was measured with computed tomography, 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG-PET) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). KRAS and EGFR mutations were assessed in tumor samples.Results: Forty-seven patients were included. Median follow-up was 15.2 months. NPR at 6 weeks was 75{\%}. Median progression-free survival (PFS) was 3.8 [95{\%} confidence interval (CI) 2.3-5.4] months and median overall survival (OS) was 6.9 (95{\%} CI 5.5-8.4) months. Toxicity was mainly mild. The presence of KRAS (n = 10) or EGFR mutations (n = 5) did not influence outcome. After 3 weeks of treatment, >20{\%} decrease in standard uptake value as measured with positron emission tomography predicted for longer PFS (9.7 versus 2.8 months; P = 0.01) and >40{\%} decrease in K(trans) as assessed by DCE-MRI did not predict for longer PFS.Conclusions: First-line treatment with bevacizumab and erlotinib in stage IIIb/IV NSCLC resulted in an NPR of 75{\%}. OS was however disappointing. Early response evaluation with FDG-PET is the best predictive test for PFS.",
keywords = "bevacizumab, chemonaive, erlotinib, imaging, NSCLC, phase II, GROWTH-FACTOR RECEPTOR, POSITRON-EMISSION-TOMOGRAPHY, CISPLATIN PLUS GEMCITABINE, ANTIBODY BEVACIZUMAB, COLORECTAL-CANCER, CHEMOTHERAPY, TRIAL, INHIBITOR, THERAPY, TUMOR",
author = "Dingemans, {A. -M. C.} and {de Langen}, {A. J.} and {van den Boogaart}, V. and Marcus, {J. T.} and Backes, {W. H.} and Scholtens, {H. T. G. M.} and {van Tinteren}, H. and Hoekstra, {O. S.} and J. Pruim and B. Brans and Thunnissen, {F. B.} and Smit, {E. F.} and Groen, {H. J. M.}",
year = "2011",
month = "3",
doi = "10.1093/annonc/mdq391",
language = "English",
volume = "22",
pages = "559--566",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "3",

}

RIS

TY - JOUR

T1 - First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer

T2 - a phase II study including molecular imaging

AU - Dingemans, A. -M. C.

AU - de Langen, A. J.

AU - van den Boogaart, V.

AU - Marcus, J. T.

AU - Backes, W. H.

AU - Scholtens, H. T. G. M.

AU - van Tinteren, H.

AU - Hoekstra, O. S.

AU - Pruim, J.

AU - Brans, B.

AU - Thunnissen, F. B.

AU - Smit, E. F.

AU - Groen, H. J. M.

PY - 2011/3

Y1 - 2011/3

N2 - Background: Both bevacizumab and erlotinib have clinical activity in non-small-cell lung cancer (NSCLC). Preclinical data suggest synergistic activity.Patients and methods: Chemonaive patients with stage IIIb or IV non-squamous NSCLC were treated with bevacizumab 15 mg/kg every 3 weeks and erlotinib 150 mg daily until progression. Primary end point was non-progression rate (NPR) at 6 weeks. Tumor response was measured with computed tomography, 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG-PET) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). KRAS and EGFR mutations were assessed in tumor samples.Results: Forty-seven patients were included. Median follow-up was 15.2 months. NPR at 6 weeks was 75%. Median progression-free survival (PFS) was 3.8 [95% confidence interval (CI) 2.3-5.4] months and median overall survival (OS) was 6.9 (95% CI 5.5-8.4) months. Toxicity was mainly mild. The presence of KRAS (n = 10) or EGFR mutations (n = 5) did not influence outcome. After 3 weeks of treatment, >20% decrease in standard uptake value as measured with positron emission tomography predicted for longer PFS (9.7 versus 2.8 months; P = 0.01) and >40% decrease in K(trans) as assessed by DCE-MRI did not predict for longer PFS.Conclusions: First-line treatment with bevacizumab and erlotinib in stage IIIb/IV NSCLC resulted in an NPR of 75%. OS was however disappointing. Early response evaluation with FDG-PET is the best predictive test for PFS.

AB - Background: Both bevacizumab and erlotinib have clinical activity in non-small-cell lung cancer (NSCLC). Preclinical data suggest synergistic activity.Patients and methods: Chemonaive patients with stage IIIb or IV non-squamous NSCLC were treated with bevacizumab 15 mg/kg every 3 weeks and erlotinib 150 mg daily until progression. Primary end point was non-progression rate (NPR) at 6 weeks. Tumor response was measured with computed tomography, 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG-PET) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). KRAS and EGFR mutations were assessed in tumor samples.Results: Forty-seven patients were included. Median follow-up was 15.2 months. NPR at 6 weeks was 75%. Median progression-free survival (PFS) was 3.8 [95% confidence interval (CI) 2.3-5.4] months and median overall survival (OS) was 6.9 (95% CI 5.5-8.4) months. Toxicity was mainly mild. The presence of KRAS (n = 10) or EGFR mutations (n = 5) did not influence outcome. After 3 weeks of treatment, >20% decrease in standard uptake value as measured with positron emission tomography predicted for longer PFS (9.7 versus 2.8 months; P = 0.01) and >40% decrease in K(trans) as assessed by DCE-MRI did not predict for longer PFS.Conclusions: First-line treatment with bevacizumab and erlotinib in stage IIIb/IV NSCLC resulted in an NPR of 75%. OS was however disappointing. Early response evaluation with FDG-PET is the best predictive test for PFS.

KW - bevacizumab

KW - chemonaive

KW - erlotinib

KW - imaging

KW - NSCLC

KW - phase II

KW - GROWTH-FACTOR RECEPTOR

KW - POSITRON-EMISSION-TOMOGRAPHY

KW - CISPLATIN PLUS GEMCITABINE

KW - ANTIBODY BEVACIZUMAB

KW - COLORECTAL-CANCER

KW - CHEMOTHERAPY

KW - TRIAL

KW - INHIBITOR

KW - THERAPY

KW - TUMOR

U2 - 10.1093/annonc/mdq391

DO - 10.1093/annonc/mdq391

M3 - Article

VL - 22

SP - 559

EP - 566

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 3

ER -

ID: 5282127